Becton, Dickinson and Company $BDX Stake Cut by Hsbc Holdings PLC

Hsbc Holdings PLC decreased its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 5.4% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 645,767 shares of the medical instruments supplier’s stock after selling 36,591 shares during the period. Hsbc Holdings PLC owned about 0.23% of Becton, Dickinson and Company worth $97,770,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of BDX. Auto Owners Insurance Co grew its position in shares of Becton, Dickinson and Company by 22,225.2% during the 4th quarter. Auto Owners Insurance Co now owns 40,711,035 shares of the medical instruments supplier’s stock valued at $790,079,000 after buying an additional 40,528,680 shares during the last quarter. BlackRock Inc. bought a new position in Becton, Dickinson and Company in the second quarter worth about $3,721,533,000. State Street Corp lifted its holdings in Becton, Dickinson and Company by 0.8% in the fourth quarter. State Street Corp now owns 13,989,132 shares of the medical instruments supplier’s stock worth $2,714,871,000 after acquiring an additional 116,737 shares during the last quarter. First Eagle Investment Management LLC boosted its stake in Becton, Dickinson and Company by 16.5% in the fourth quarter. First Eagle Investment Management LLC now owns 11,646,000 shares of the medical instruments supplier’s stock valued at $2,260,139,000 after acquiring an additional 1,651,592 shares during the period. Finally, Geode Capital Management LLC grew its holdings in shares of Becton, Dickinson and Company by 0.8% during the fourth quarter. Geode Capital Management LLC now owns 6,885,361 shares of the medical instruments supplier’s stock valued at $1,331,165,000 after purchasing an additional 53,884 shares during the last quarter. 86.97% of the stock is owned by institutional investors and hedge funds.

Becton, Dickinson and Company Price Performance

NYSE BDX opened at $190.22 on Thursday. Becton, Dickinson and Company has a 12 month low of $127.59 and a 12 month high of $193.07. The firm has a market capitalization of $52.41 billion, a PE ratio of 57.30, a P/E/G ratio of 13.38 and a beta of 0.19. The company’s 50 day simple moving average is $164.35 and its 200 day simple moving average is $160.49. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.51.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, topping analysts’ consensus estimates of $3.14 by $0.09. The firm had revenue of $4.98 billion during the quarter, compared to the consensus estimate of $4.89 billion. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%.The firm’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $3.68 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, equities research analysts forecast that Becton, Dickinson and Company will post 12.67 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be issued a $1.05 dividend. The ex-dividend date is Wednesday, September 9th. This represents a $4.20 annualized dividend and a dividend yield of 2.2%. Becton, Dickinson and Company’s dividend payout ratio is 126.51%.

Analysts Set New Price Targets

BDX has been the topic of a number of research reports. Citigroup reiterated a “buy” rating on shares of Becton, Dickinson and Company in a research report on Thursday, August 13th. Evercore set a $180.00 target price on Becton, Dickinson and Company in a research report on Monday, July 6th. Bank of America reduced their price target on shares of Becton, Dickinson and Company from $177.00 to $170.00 in a report on Friday, June 12th. Wells Fargo & Company increased their price objective on shares of Becton, Dickinson and Company from $161.00 to $170.00 and gave the stock an “equal weight” rating in a report on Friday, August 7th. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $210.00 price objective on shares of Becton, Dickinson and Company in a research report on Thursday, August 6th. Eight analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $185.67.

Insider Activity at Becton, Dickinson and Company

In other news, CEO Thomas E. Polen, Jr. sold 4,152 shares of the firm’s stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $185.00, for a total transaction of $768,120.00. Following the completion of the transaction, the chief executive officer owned 110,163 shares in the company, valued at approximately $20,380,155. This trade represents a 3.63% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael David Garrison sold 1,100 shares of Becton, Dickinson and Company stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $145.66, for a total transaction of $160,226.00. Following the completion of the transaction, the executive vice president directly owned 13,172 shares in the company, valued at $1,918,633.52. This represents a 7.71% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 11,704 shares of company stock valued at $1,963,618 over the last 90 days. 0.40% of the stock is currently owned by corporate insiders.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.